Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products March 16, 2026-- Sentynl Therapeutics Inc. (" Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (" Zydus"), announced that it is entering into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license it

Strategy May Bolster Blood Cancer Therapy and Move HIV Research Closer to a Cure March 13, 2026 -- A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into patients to fight cancer and HIV, addressing a major limitation of current treatments. Their findings, published today in Science Advances, describe a manufacturing approach that, compared to the existing

If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe plaque psoriasis; FDA decision expected by October 29, 2026 With 1 in 3 psoriasis patients developing psoriatic arthritis, Sun Pharma remains committed to better serving patients living with psoriatic disease March 16, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA,

-Global Phase II open-label study in adult HAE patients ongoing, company on track for primary completion of study in the second half of 2026 March 16, 2026 -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its novel siRNA therapy BW-20805, for the treatment of hereditary angioedema (HAE) . BW-20805 is an investigat

Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer March 13, 2026 -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with int

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries. The new arrangement builds upon the existing licence and manufacturing partnership between the

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 * GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has expanded the approved age indication of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV. AREXVY was previously approved in the US for the prevention of RSV-related LRTD in adults aged

Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 March 13, 2026 --- Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will

Ultragenyx Pharmaceutical said Thursday that its experimental gene therapy DTX301 (avalotcagene ontaparvovec) met one of the main goals in a late-stage trial of ornithine transcarbamylase (OTC) deficiency, helping control ammonia levels in patients with the disorder. The therapy, delivered as a single intravenous infusion using an AAV8 vector, is designed to provide stable expression and activity of the OTC enzyme, addressing the genetic defect that prevents patients from properly detoxifying a

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 – March 12, 202 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the first